Publication Year

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Reichert H, McMahon LF, Meddings J. Did hospital-acquired pressure ulcer rates decrease after implementation of non-payment as a comorbidity with the 2008 Hospital-Acquired Conditions Initiative? Presented at the Academy Health Annual Research Meeting, San Diego, CA, June 2014.

Meddings J, Reichert H, Dueweke E, Rhyner J. 2014. Issues regarding identification of urinary catheter use from medical records. In: Battles JB, Cleeman JI, Kahn KK, Weinberg DA, eds. Advances in the Prevention and Control of Healthcare-Associated Infections. Rockville (MD): Agency for Healthcare Research and Quality (US).

Reichert H. Qualtrics (and other survey tools): Beyond opinion surveys. Presented at the University of Michigan Institute for Healthcare Policty and Innovation (IHPI) Methods Seminar, Ann Arbor, MI, February 2014.

Reichert H, Welch K. Conceptualizing statistics: A heuristic approach. Presented at the University of Michigan’s Division of General Medicine Spring Retreat, Ann Arbor, MI, May 2014.

Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays S, Hixon JG, Harris MA. 2014. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 34(5):525-536. doi: 10.1002/jat.2907. PMID: 23943231.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis. Abstract C14, Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo, 2014.